Reply

Affiliations

¹ Johns Hopkins University School of Medicine, Baltimore, MD.
² Harvard University and Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Cambridge, MA and Howard Hughes Medical Institute, Brigham and Women's Hospital and Harvard University School of Medicine, Boston, MA.
³ Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA and Harvard University School of Medicine, Boston, MA.

Comment

Ami A Shah et al. Arthritis Rheumatol. 2017 Sep.

. 2017 Sep;69(9):1915-1916.

doi: 10.1002/art.40132. Epub 2017 Jul 11.

¹ Johns Hopkins University School of Medicine, Baltimore, MD.
² Harvard University and Harvard-Massachusetts Institute of Technology, Division of Health Sciences and Technology, Cambridge, MA and Howard Hughes Medical Institute, Brigham and Women's Hospital and Harvard University School of Medicine, Boston, MA.
³ Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, MA and Harvard University School of Medicine, Boston, MA.

No abstract available

Comment on

Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.
Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L. Shah AA, et al. Arthritis Rheumatol. 2017 Jun;69(6):1306-1312. doi: 10.1002/art.40065. Arthritis Rheumatol. 2017. PMID: 28217959 Free PMC article.
Understanding the Role of Antibodies as Markers of Cancer-Associated Systemic Sclerosis: Comment on the Article by Shah et al.
Bernal-Bello D, Guillén-Del Castillo A, Selva-O'Callaghan A, Fonollosa-Pla V, de Tena JG, Simeón-Aznar CP. Bernal-Bello D, et al. Arthritis Rheumatol. 2017 Sep;69(9):1914-1915. doi: 10.1002/art.40129. Epub 2017 Jul 11. Arthritis Rheumatol. 2017. PMID: 28426925 No abstract available.